Compare LICN & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LICN | TXMD |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 24.4M |
| IPO Year | 2021 | 2012 |
| Metric | LICN | TXMD |
|---|---|---|
| Price | $1.26 | $2.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 524.4K | 60.0K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $200.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.75 | $0.98 |
| 52 Week High | $9.49 | $2.95 |
| Indicator | LICN | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 38.17 | 47.99 |
| Support Level | $0.75 | $1.90 |
| Resistance Level | $3.33 | $2.16 |
| Average True Range (ATR) | 0.54 | 0.15 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 8.05 | 35.48 |
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational, and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and the sales of financial and taxation training software.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.